Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort).
Santos ME, Protopopescu C, Sogni P, Yaya I, Piroth L, Bailly F, Marcellin F, Esterle L, Wittkop L, Rosenthal E, Morlat P, Roux P, de Araujo WN, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Santos ME, et al. Among authors: wittkop l. AIDS Behav. 2020 Apr;24(4):1069-1084. doi: 10.1007/s10461-019-02585-7. AIDS Behav. 2020. PMID: 31286317
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort. Wittkop L, et al. J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31. J Antimicrob Chemother. 2009. PMID: 19336453 Free PMC article. Clinical Trial.
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B. da Silva D, et al. Among authors: wittkop l. J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12. J Antimicrob Chemother. 2010. PMID: 20388636
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord; Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, et al. Int J Epidemiol. 2012 Apr;41(2):433-45. doi: 10.1093/ije/dyr164. Epub 2011 Nov 28. Int J Epidemiol. 2012. PMID: 22493325 Free article.
Associations between immune depression and cardiovascular events in HIV infection.
Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group. Sabin CA, et al. AIDS. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3. AIDS. 2013. PMID: 23842128
Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Miailhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, Sogni P, Fontaine H, Rosenthal E, Winnock M, Loko MA, Wittkop L, Dabis F, Salmon D; ESCMID European Study Group on Viral Hepatitis. Miailhes P, et al. Among authors: wittkop l. Liver Int. 2015 Sep;35(9):2090-9. doi: 10.1111/liv.12799. Epub 2015 Feb 23. Liver Int. 2015. PMID: 25650873
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Bruyand M, et al. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523. J Acquir Immune Defic Syndr. 2015. PMID: 25763785
Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Mocroft A, et al. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25826420 Free PMC article.
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, Neau D, Morlat P, Loko MA, Wittkop L, Dabis F; ANRS CO13HEPAVIH study group. Salmon D, et al. Among authors: wittkop l. J Clin Virol. 2015 Dec;73:32-35. doi: 10.1016/j.jcv.2015.10.010. Epub 2015 Oct 19. J Clin Virol. 2015. PMID: 26528903
176 results